Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1[alpha], and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK； derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.本發明所揭示的方法是基於發現當使用GV1001胜肽(EARPALLTSRLRFIPK；源自人類端粒酶蛋白)進行免疫接種或當視情況需要而合併使用現行的吉西他賓與卡培他賓之合併用藥治療時，嗜酸粒細胞趨化蛋白、MIP1α及CRP在血清及血漿中的含量可作為用來判斷誘發免疫反應以治療癌症之可行性的重要生物標記。特別是，本發明提供用來判斷患者是否應施以GV1001治療及判斷是否繼續進行誘發治療的方法。
